Clinical manifestation of myeloperoxidase deficiency.
Myeloperoxidase (MPO), an iron-containing heme protein localized in the azurophilic granules of neutrophil granulocytes and in the lysosomes of monocytes, is involved in the killing of several micro-organisms and foreign cells, including bacteria, fungi, viruses, red cells, and malignant and nonmalignant nucleated cells. Despite the primary role of the oxygen-dependent MPO system in the destruction of certain phagocytosed microbes, subjects with total or partial MPO deficiency generally do not have an increased frequency of infections, probably because other MPO-independent mechanism(s) for microbicidal activity compensate for the lack of MPO. Infectious diseases, especially with species of Candida, have been observed predominantly in MPO-deficient patients who also have diabetes mellitus, but the frequency of such cases is very low, less than 5% of reported MPO-deficient subjects. Evidence from a number of investigators indicates that individuals with total MPO deficiency show a high incidence of malignant tumors. Since MPO-deficient PMNs exhibit in vitro a depressed lytic action against malignant human cells, it can be speculated that the neutrophil MPO system plays a central role in the tumor surveillance of the host. However, any definitive conclusion on the association between MPO deficiency and the occurrence of cancers needs to be confirmed in further clinical studies. Clinical manifestations of this disorder depend on the nature of the defect; an acquired abnormality associated with other hematological or nonhematological diseases has been occasionally described, but the primary deficiency is the form more commonly reported. Another area of interest pertinent to MPO expression is related to the use of anti-MPO monoclonal antibodies for the lineage assignment of acute leukemic cells, the definition of FAB MO acute myeloid leukemia, the identification of biphenotypic acute leukemias, and their distinction from acute leukemia with minimal phenotypic deviation. The advantage of MPO monoclonal antibodies over the MPO cytochemical assay relies in the ability of the former method to recognize the enzymatically inactive precursor forms of MPO.
Lanza
F
F
Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, St. Anna Hospital, Italy.
D000208:Acute Disease; D000911:Antibodies, Monoclonal; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000201:enzymology; D006801:Humans; D007938:Leukemia / Q000175:diagnosis; D008659:Metabolic Diseases / Q000145:classification / Q000150:complications / Q000503:physiopathology*; D008661:Metabolism, Inborn Errors / Q000145:classification / Q000150:complications / Q000503:physiopathology*; D009369:Neoplasms / Q000150:complications; D009504:Neutrophils / Q000201:enzymology; D009195:Peroxidase / Q000172:deficiency* / Q000276:immunology / Q000378:metabolism; D010544:Peroxidases / Q000172:deficiency
D000911:Antibodies, Monoclonal; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D009195:Peroxidase